The phenomenon of angiogenesis-the growth of capillary blood vessels and the development of new blood vesselshas been familiar to morphologists and physiologists since the late 19th century. Most of the early research revolved around tumour neovascularization and was initiated by Goldman who published a key paper in 19071. The pioneering work of Folkman began in the early 1960s and was directed mainly at elucidating the mechanisms of early tumour angiogenesis2. Under normal conditions, angiogenesis is highly regulated and occurs when an imbalance exists between the supply and demand of oxygen and nutrients to a vascular bed, or if inflammation is present. Initially the concept of angiogenesis was resisted, because tumour hypervascularity was believed to result from dilatation of pre-existing host vessels rather than growth and development of vessels de novo. Opinions changed, however, when avascular rabbit corneas were seen to acquire new vessels when implanted with tumours; and these studies eventually led to the isolation and purification of an angiogenic factor from tumour cells3. For a time it was thought that angiogenic initiating factors must be endothelial mitogens. Basic fibroblast growth factor (b-FGF), first purified by Shing and Folkman, is an endothelial mitogen4; but the next angiogenic factor to be discovered, angiogenin, was not5. Whereas Folkman6 and his associates were instrumental in establishing the basic mechanisms of tumour vessel growth and development, it was Schaper who greatly increased our understanding of angiogenesis in the heart and the development of the coronary collateral circulation7. Since the work of these early investigators, the advent of recombinant technology and the development of novel drug delivery and biocompatible systems to deliver peptides have increased the potential for both scientific investigation and therapeutic angiogenesis. The fact that collateral vessels develop and grow during gradual coronary occlusion in animal models and in patients, along with the observation that certain mitogenic growth factors and cytokines can induce angiogenesis, suggests that angiogenic substances could be of value in the treatment of occlusive coronary artery disease. Currently, myocardial ischaemia and its consequences can be treated with coronary artery bypass grafting (CABG), percutaneous transluminal coronary angioplasty (PTCA), and more recently with transmyocardial laser revascularization (TMLR). However, a subset of patients exists who are not candidates for CABG, PTCA or other conventional methods of revascularization. The lack of efficacy and hazards of TMLR leave a void that may be filled by other approaches such as therapeutic angiogenesis. Here we discuss the potential mechanisms and the therapeutic implications.
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PATHOPHYSIOLOGY OF ANGIOGENESIS
In normal adult coronary arteries, endothelial and vascular smooth muscle cells are mitotically inactive8. However, during growth and development and under conditions of ischaemia, hypoxia, inflammation or other stresses, these cells begin to migrate and divide. Blood vessel formation passes through several steps including dissolution of the bond between the endothelium and the underlying basement membrane, migration, adhesion and reattachment of the endothelial cells, proliferation and tube formation culminating in the development of a new capillary. The cellular and molecular changes required for this process are numerous, complex and as yet poorly understood.
Collateral vessel formation can arise either from true angiogenesis or from vasculogenesis. Angiogenesis refers to the sprouting of capillaries and small non-muscular vessels from pre-existing capillaries and is the predominant mechanism for increasing collateral blood flow in chronic myocardial ischaemia. Vasculogenesis refers to the de novo embryological development of blood vessels from angioblasts and generally leads to the formation of larger muscular arteries8. Despite the distinct molecular mechanisms for these two processes, practically speaking they have similar effects in maintaining myocardial perfusion during and after coronary occlusion. Thus, angiogenesis is widely used as a generic term for both processes. After acute occlusion of a major coronary artery, epicardial collaterals help to maintain perfusion via the enlargement of preexisting arterioles. When the occlusion is gradual, formation of new vessels plays a greater part in preserving blood flow; moreover, subendocardial perfusion is maintained more by true angiogenesis and less by recruitment of native vessels9' 0. The effects of physical exercise are largely confined to angiogenesis and collateral perfusion, which are augmented; exercise is less effective in promoting new epicardial muscular vessels (vasculogenesis)12.
HYPOXIA AND ISCHAEMIA Several animal models of coronary occlusion have been useful for the examination of collateral-dependent perfusion and of function in the myocardium. These include the ameroid occluder model in which a steel ring surrounding a hydrophilic plastic is placed around a coronary artery9 10.
This method generally occludes the artery over 10-20 days. Other commonly used methods are the embolization model, in which small particles (about 25 pm) are injected into a coronary artery13, and the intermittent coronary occlusion model in which a pneumatic occluder surrounding the artery is inflated at regular intervals. Since even gradual occlusion of a major coronary artery is associated with areas of infarction, and with subnormal myocardial perfusion during pacing or stress, angiogenesis is generally not sufficient to prevent tissue ischaemia entirely.
What are the stimuli for development of new vessels? Clearly there is more to the question than hypoxia and ischaemia. On angiography, collateral vessels are sometimes observed around a coronary occlusion in a region that has not been deprived of blood and oxygen. Furthermore, lower limb ischaemia is not associated with distal limb angiogenesis but rather with the development of collateral channels around the site of proximal occlusion8. The presence of an interface between normal and ischaemic or hypoxic tissues may contribute or be critical to the angiogenic process.
ROLE OF INFLAMMATION
Studies in both animals and patients have suggested that inflammation itself leads to new blood vessel growth, especially during infection and neoplasia. Schaper8 has suggested that local stress and inflammation, rather than ischaemia per se, are the dominant factors in stimulation of angiogenesis. The presence of macrophages and neutrophils is sufficient for angiogenesis to occurl4'15 ischaemia is not a prerequisite. Myocardial ischaemia and infarction are, however, associated with infiltration by inflammatory cells and the subsequent release of cytokines including transforming growth factor beta and interleukin-6. These cytokines are capable of increasing expression of vascular endothelial growth factor (VEGF) as well as the inducible form of NO synthase. In addition, enhanced expression of adhesion molecules may lead to increased inflammation. This and the release of proteolytic enzymes and increased vascular permeability may initiate angiogenesis by lysing the 'glue' between the endothelial cells and the underlying basement membrane.
GROWTH FACTORS AND NITRIC OXIDE
The fact that angiogenesis is almost invariably associated with the production and release of growth factors suggests that these substances are critical to the formation of new blood vessels. High levels of b-FGF have been detected in the pericardial fluid of patients with unstable angina16. The process requires more than the mere presence of growth factors; their respective receptors must be upregulated and inhibitory factors must be inhibited. Angiogenesis in the heart may be associated with increased expression of various substances including acidic-fibroblast growth factor (a-FGF) and b-FGF, VEGF, and platelet-derived growth factor (PDGF). Some of the these growth factors are constitutively expressed in the myocardium, whereas others (e.g. b-FGF, PDGF)17'18 are induced only in response to a stimulus. Increased expression of b-FGF receptor-I and the VEGF receptors flt-i and flk-I is observed in both acute19 and chronic20 myocardial ischaemia, further implicating growth factors in the angiogenesis process. The high affinity of heparin to b-FGF and many other growth factors, which helped with their initial purification, has proved biologically important. For example, b-FGF is stored in the extracellular matrix bound to heparan sulphate, and heparin protects b-FGF from degradation. In addition, heparin-like molecules on the cell surface are required for the binding of b-FGF to its receptors2.
Although a strong temporal and spatial relation exists between increased expression of the above growth factors (and their receptors) and the development of new blood vessels, the causal connection remains uncertain. There is also a strong relation between the release of nitric oxide and regulation of blood vessel growth and development; again it is not well defined and at times seems contradictory. NO donors such as substance p21, and growth factors such as VEGF and b-FGF that release N02022-24, induce angiogenesis in vivo as well as causing proliferation of postcapillary endothelial cells in tissue culture. NO has also been implicated in later steps in the angiogenic process such as tube formation. Inhibitors of NO synthase suppress angiogenesis, and the proliferative effect of VEGF is also decreased in the presence of NO synthase inhibitors. Other angiogenic growth factors such as a-FGF24 elicit the release of endothelium-derived NO. Inhibitors of tyrosine kinase impair FGF signalling, translocation, and DNA synthesis in coronary venular endothelial cells; hence, the angiogenic response may be mediated through the tyrosine kinase receptor23. The stimulated synthesis and release of endothelium-derived NO by VEGF and b-FGF has been shown to be largely regulated by tyrosine kinase2O. These observations further point to a role for NO in the angiogenic process. However, other workers25 have found that sodium nitroprusside and the NO precursor L-arginine inhibit angiogenesis in the chick embryo chorioallantoic membrane, as assessed by protein synthesis and vascular density. In this same study, inhibitors of NO synthase increased these indices of angiogenesis. Thus, the exact roles of NO in the different stages of angiogenesis have not been elucidated, and may differ between species and vascular beds.
THERAPEUTIC ANGIOGENESIS

Animal studies
Several groups have examined the effects of exogenous administration of angiogenic growth factors on myocardial perfusion, function and infarct size after acute or chronic coronary occlusion. Yanagisawa-Miwa et a].26 administered b-FGF in an acute canine infarction model and demonstrated at necropsy a reduction in the infarct size and increased capillary density in the treatment group. This study led to intense interest in the potential of angiogenic growth for preventing both acute and chronic ischaemic damage in the heart.
What do we know about long-term effects? Calcium alginate microcapsules containing b-FGF have been used to deliver the growth factor continuously over several weeks in a porcine ameroid occluder model. This resulted in a reduction in infarct size and in better myocardial perfusion and contractility in the ischaemic zone27. Similar beneficial results have been obtained with daily injection of b-FGF into an indwelling catheter in the left atrium28. Attempts at intravascular infusion of a-FGF have met with negligible success29; however, the administration of a longer-half-life mutant form to the epicardial surface via a slow-release device improved coronary blood flow and myocardial function in the chronically ischaemic territory30.
When VEGF was injected in a single bolus into the left coronary ostium of pigs, myocardial perfusion and function improved (as determined by coloured microsphere analysis and 2D echocardiography), but half the animals died from NO-mediated hypotension31. In contrast, long-term perivascular administration of VEGF improved myocardial perfusion and function in models of chronic ischaemia32'33.
Recently, the administration of fibroblast growth factor by adenovirus-mediated gene transfer has been reported to augment myocardial perfusion and increase capillary density34. Thus, growth factor therapy is feasible not only by perivascular or intravascular delivery of the protein but also by gene therapy.
One potential gain from growth factor therapy is the preservation of vascular responses. In the collateral circulation and the collateral-dependent circulation vasomotor regulation is abnormal; for example, collateral vessels are hyperresponsive to vasopressin and lack functioning alpha-adrenergic receptors35, and microvessels from the collateral-dependent myocardium show impaired endothelium-dependent relaxation and subnormal 13-adrenergic responses. After administration of b-FGF or VEGF, endothelium-dependent relaxation is preserved36 and /3adrenoceptor-mediated responses become normal37 in the collateral-dependent circulation.
Trials in man
Isner et al. 38 reported augmentation of collateral vessel formation in a patient with peripheral vascular disease four weeks after direct intra-arterial gene transfer of a plasmid (ph VEGF165) encoding for VEGF. The plasmid was applied to a hydrogel polymer coating of an angioplasty balloon. With balloon inflation the plasmid was released distally. In a phase 1 clinical trial begun at our institution, b-FGF is administered via a calcium alginate polymer slow-release device to a non-bypassable myocardial region during coronary artery bypass surgery. In this trial, which continues, patients are evaluated by nuclear magnetic resonance perfusion imaging before and three months after initiation of growth factor treatment. In similar trials b-FGF or VEGF will be delivered by intravascular injection or perivascular administration of the protein or by transvascular delivery of DNA coding the growth factor in patients with atherosclerotic coronary and peripheral vascular insufficiency39.
Although the exact stimulus for angiogenesis remains controversial few challenge the notion that growth of new collateral vessels in the heart has the potential to reduce fatal consequences and morbidity after coronary artery occlusion. Initial clinical results with VEGF recombinant protein in the ischaemic limb and b-FGF in the heart have been encouraging, in that improved vascularity and clinical safety have been observed. Direct administration of the angiogenic protein has the merit of simplicity, since it does not require incorporation of a gene into the nucleus. However, gene therapy encoding the protein may be preferable for several reasons. The cost of scaling up from research-grade to human-quality recombinant protein and the reimbursement for recombinant protein therapies in the future remain uncertain. The potential for maintaining a desired concentration of VEGF or other growth factor by direct application may be less than that by gene transfection in the arterial wall with endogenous local production. We do not, however, know how long VEGF, b-FGF or other growth factors will be secreted after gene therapy.
As with all new forms of therapy, one must try to predict drawbacks and complications before general application. There is a theoretical possibility that the VEGF gene could augment the growth of small dormant tumours or interfere with malignant cell surveillance. Patients with type 1 diabetes mellitus might be at risk of deterioration of vision or renal function from VEGF-induced neovascularity or direct toxic actions. With viral vectors for gene transfer, few adverse effects have so far emerged but there is the possibility that, after taking up foreign DNA, a normal cell might be transformed to abnormal, with catastrophic results. These matters will be examined in preliminary work, along with bioactivity and the optimum delivery method. On existing evidence, the patients who might gain most from growth factor therapy are those who have diffusely diseased or very small coronary vessels and are not candidates for bypass surgery or angioplasty.
What is the best growth factor or combination of growth factors for inducing angiogenesis in acute or chronic coronary artery disease? In animal studies no single growth factor has proved greatly superior to another; however, b-FGF and VEGF are reported to be synergistic in vivo40. These questions apart, technical considerations such as ease of delivery, route of administration, and toxicity need to be resolved. There are numerous options for delivery. Growth factors may be applied to the perivascular epicardium in conjunction with coronary bypass surgery, as is now being done at our institution. Alternatively, they may be injected directly in paste or liquid form through a sternotomy, by thoracoscopic methods, or percutaneously with a long needle. In addition, several methods of catheter-based delivery are being investigated, such as bolus intracoronary infusion and transvascular injection via a needle or balloon catheter with side perforations. Since intra-arterial administration of VEGF and b-FGF has proved effective in limiting infarction and restoring myocardial perfusion and function in animals, these methods may ultimately have the greatest clinical application.
Therapeutic angiogenesis in the heart is an exciting area of research with the potential for improving and reducing the cost of care of patients with ischaemic coronary artery disease. We do not envisage that it will do away with bypass surgery and angioplasty but rather that it will augment them. Furthermore, therapeutic angiogenesis may extend treatment options to patients who are not good candidates for conventional methods of revascularization. Several clinical trials are underway or being planned, and we hope that answers to the questions raised in this paper will soon be forthcoming.
